Barclays views Illumina’s (ILMN) guidance last night as largely as expected. The bulls are going to defend the stock on China being de-risked, ...

In a report released today, Luke Sergott from Barclays maintained a Sell rating on Illumina (ILMN – Research Report), with a price target of ...

Today, Benzinga's options scanner identified 8 options transactions for Illumina. This is an unusual occurrence. The ...

Illumina (NASDAQ:ILMN – Get Free Report) was downgraded by investment analysts at Barclays from an “equal weight” rating to an “underweight” rating in a research note issued on Monday ...

Other research analysts have also issued reports about the stock. Barclays lowered shares of Illumina from an “equal weight” rating to an “underweight” rating and dropped their price ...

Illumina (NASDAQ:ILMN) has been cut to underweight from equal weight by Barclays over concerns the company may be facing sanctions in China and risks to its 2025 and long-range guidance.

11 analysts have expressed a variety of opinions on Illumina ILMN over the past quarter, offering a diverse set of opinions from bullish to bearish. Summarizing their recent assessments ...

Gene-sequencing giant Illumina is laying off 96 employees from its San Diego headquarters, according to paperwork filed with the state. This workforce reduction comes at a time when Illumina is ...

Illumina Inc (NASDAQ:ILMN)., a leading player in the genomic sequencing industry, finds itself at a critical juncture as it navigates a shifting competitive landscape and global economic challenges.

The Chinese government took its economic sanctions against San Diego-based Illumina a step further Tuesday by banning the gene-sequencing company from importing its machines to the country.